Aktiesnakken — Marts 2010
-
det dobbelte af hvad de tjente de siste 6 uger for hele 2010....
-
humlen i franks betragtninger er jo, at han ikke mener at arzerra vil sælge og egfr vil fejle totalt. Så er der kun omkostninger
tilbage -
Det tør han bare ikke sige - da han så har lagt sin analytikerrøv i klaskehøjde
-
novo får fda approval
-
Genmab S/P gentager køb
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind